European Commission Approved Susvimo for nAMD
The regulatory approval allows for the use of a refillable eye implant to treat macular degeneration.
Updated on Sept. 21, 2026 in Biotech
Live Poll
Would you prefer a continuous medication implant over regular monthly eye injections for chronic eye conditions?
The European Commission has approved Susvimo for the treatment of neovascular age-related macular degeneration. The implantable device allows for continuous drug delivery, requiring only two treatments per year.
Why it matters
Susvimo offers an alternative to the frequent eye injections typically required for managing nAMD. The technology aims to reduce the treatment burden for patients while maintaining vision stability.
Susvimo utilizes the Contivue Port Delivery Platform to provide continuous release of ranibizumab. Long-term data indicates successful vision maintenance for up to seven years with this refillable system.
The players
European Commission
This is the executive branch of the European Union responsible for proposing legislation and implementing decisions.
Roche
Headquartered in Basel, Switzerland, this multinational healthcare company focuses on pharmaceuticals and diagnostics.
The details
The device is inserted through a one-time outpatient surgical procedure to facilitate medicine delivery. It is designed to support the estimated 1.7 million people in the European Union living with neovascular age-related macular degeneration.
Timeline
In 2025, Roche received a CE mark for the Contivue Port Delivery Platform.
On September 21, 2026, the European Commission approved Susvimo for nAMD treatment.
The Tech Race
The approval of the Contivue Port Delivery Platform represents a significant shift from frequent injections to sustained-release implants in ophthalmology. This technology positions Roche to compete against legacy delivery methods by reducing the number of clinical visits required annually.
Patients with neovascular age-related macular degeneration may transition to a schedule of two treatments per year instead of more frequent interventions. This shift could streamline clinical management for those currently relying on standard anti-VEGF injections.
The takeaway
This approval highlights a growing trend toward implantable drug delivery systems that simplify long-term chronic disease management. Patients and providers should discuss if this implantable option is suitable based on individual eye health history.
Further reading
Learn more about the latest advancements in the field in the Biotech section.
More information
For additional details, visit the Roche corporate information portal.
Live Poll
Would you prefer a continuous medication implant over regular monthly eye injections for chronic eye conditions?
